Caliper to Release Q2 Financial Results; Hold Conference Call
Caliper Life Sciences said that it plans to release its second quarter financial results on Thursday, Aug. 5, at 8:00 a.m. EDT.
Caliper will hold a conference call and live webcast to discuss the results later that day, at 12:30 p.m. EDT.
Serologicals Completes Acquisition of AltaGen Biosciences
Serologicals said last week that it has completed the acquisition of AltaGen Biosciences and its subsidiary, Sierra BioSource. The acquisition was originally announced on June 30.
According to an official statement, the Sierra acquisition “enables Serologicals to more broadly address the cell culture market by providing custom research and development services and custom media formulation, as well as to accelerate its cell culture product development.”
Serologicals said it expected the acquisition to be accretive in fiscal year 2004. Additional financial details were not disclosed.
Evotec and ActivBiotics Forge Drug Discovery Agreement
Hamburg, Germany-based Evotec and Lexington, Mass.-based ActivBiotics announced last week that they have entered into a joint drug discovery project.
Under the terms of the agreement, Evotec will apply Evorationale, its rational drug design platform, to one of ActivBiotics’ anti-infective lead optimization programs.
The EVOrationale platform, according to the companies, provides de novo structure determination, validation of screening hits, and structure-guided lead optimization programs. Evotec said it has applied the platform to a range of drug targets, including kinases, GPCRs, proteases, enzymes, and complex protein-ligand interactions.
Financial terms of the deal were not disclosed.
Molecular Devices to Repurchase Shares
Molecular Devices’ board of directors has approved a plan for the company to repurchase up to an aggregate of 1.5 million shares of its common stock, the company said last week.
“Based on current market prices, we believe that our stock is undervalued and that the repurchase program is a good investment of available funds,” Joseph Keegan, MD’s president and CEO, said in an official statement.
MD said the repurchases will be made occasionally on the open market at prevailing market prices or in negotiated transactions off the market.
SRI to Hold Pharma & Biotech Business Intelligence Summit in September
The Strategic Research Institute announced that its fourth annual Pharma & Biotech Business Intelligence Summit will be held on Sept. 20 and 21 in Princeton, NJ, at the Westin Princeton at Forrestal Village.
The conference will be chaired by Daniel Pascheles, vice president and head of corporate CI for Aventis Pharma. SRI said that the conference promises presentations by an array of biotech and pharma industry leaders, and will tackle subjects including, but not limited to:
• Best practices and case studies on developing cost-effective and reliable intelligence
• Business intelligence in R&D strategy
• New techniques for effective pipeline assessment
• Aligning business intelligence with R&D initiatives and strategic business development
EMBL-DKFZ Chemical Genomics Facility Taps Tripos for Lead Identification
Tripos has been selected by the European Molecular Biology Laboratory and the German Cancer Research Center to assist in the rapid identification of potential molecular leads, Tripos said.
Tripos, a drug-discovery chemistry and informatics company based in St. Louis, will use its technologies to facilitate rapid hit-finding, hit follow-up and chemical optimization of candidate molecules, the company said. Financial terms of the deal were not disclosed.
EMBL and DKFZ jointly established the Chemical Genomics Facility, one of the first European academic small-molecule screening facilities in Heidelberg, Germany.